Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease seen in pregnancy. By definition, ICP is apprehended to pregnancy and the post delivery period and is characterised following debarring of all other causes of cholestasis. Intrahepatic cholestasis of pregnancy affects 0·1–2% of pregnant women.
Materials and Method: It is a retrospective study done at Teerthanker Mahaveer medical and research center, department of obstetrics and gynaecology including 128 females with intrahepatic cholestasis of pregnancy over a period of 2 years.
Results: The mean age of the study population was 26.09±4.90 years and mean Gestational Age of the study population was 37.15±3.09 weeks. The clinical symptom of Jaundice was reported among 24.22% and Generalised Pruritus in second and third trimester was seen in all the patients. ALP was elevated in 44.44%, SGOT in 79.26%, SGPT in 73.33%, Total Serum bilirubin in 76.30%, Hypoglycemia in 11.11% and HbSAg was positive in 2.22% women. The perinatal outcome showed that Meconium was found in 37.04%, Apgar score at 1 minute (< 7) in 12.59%, Apgar score at 5 minutes (< 7) in 8.89%, Hyperbilirubinemia in 2.96% and NICU admission in 42.96% infants. Maternal complications and co- morbidities Pre-eclampsia is seen in 21.88%, hypoglycemia 10.16%, Hbsag in 3.13%, deranged coagulation profile 7.03% and post partum haemorrhage 14.06%.
Interpretation: ICP is a comparatively frequent cause of hepatic deterioration in pregnancy. There are adverse pregnancy outcomes associated with intrahepatic cholestasis of pregnancy.